NEW YORK – DDL-920 Reversing the Symptoms of Alzheimer's Disease could mark a significant breakthrough in the treatment of this debilitating condition. While current therapies primarily focus on targeting the physical manifestations of Alzheimer's, such as amyloid plaques, a new approach is emerging. Rather than concentrating on combating the plaques associated with Alzheimer's disease, researchers
SWEDEN - Can a blood test based on the ratio of plasma phosphorylated tau 217 (p-tau217) relative to non–p-tau217 (expressed as percentage of p-tau217) combined with the amyloid-β 42 and amyloid-β 40 plasma ratio (the amyloid probability score 2 [APS2]) accurately identify Alzheimer disease in primary care and secondary care when prospectively applying predefined biomarker
NEW YORK - The scientific community has long been interested in understanding and extending human life. In a new piece of research, published in Nature,Trusted Source researchers at the Medical Research Council Laboratory of Medical Science and Imperial College London, in collaboration with Duke-NUS Medical School, administered an anti-IL-11 antibody — a drug that inhibits IL-11’s effects
Have you ever wished you could slow down the ticking clock of aging? Science might have come a smidgen closer to granting your wish. Researchers have developed a new anti-aging drug that claims to significantly increase lifespan, adding up to 25% more healthy, vibrant years. The brain behind this exciting development is none other than
WASHINGTON DC - The Food and Drug Administration approved a new Alzheimer's treatment called donanemab on Tuesday, clearing the way for the third addition to a new class of drugs aimed at slowing the brain's decline in patients facing the early stages of the disease. Branded as Kisunla by drugmaker Eli Lilly, donanemab's approval follows
KALAMAZOO–Stryker Corp. announced an agreement to acquire all of the shares of Artelon Inc., a Marietta, Ga.-based privately held maker of soft tissue fixation products for foot and ankle and sports medicine procedures. Stryker officials said the company will strengthen its offerings in the soft tissue fixation segment and highlights Stryker’s commitment to providing differentiated
NEW YORK - A new drug could put an end to cumbersome CPAP machines, which are thought to be used by some 33 million Americans to manage their sleep apnea. Roughly 39 million Americans, including President Biden, currently suffer from sleep apnea. The most common form of the disorder is obstructive sleep apnea. In OSA patients, the
LONDON - Thousands of NHS patients will be given access to groundbreaking cancer vaccines, health leaders have said, as a 55-year-old man became the first in England to receive the treatment for bowel cancer in a “landmark moment”. Thirty hospitals have so far signed up to NHS England’s Cancer Vaccine Launch Pad, which is working to fast-track patients to receive the vaccines at the earliest opportunity
GAINESVILLE, Fla - Glioblastoma is the most common type of brain cancer, affecting about 3 in every 100,000 people globally each year. Recent research shows that glioblastoma incidence is risingTrusted Source due to an aging population and environmental factors such as air pollutionTrusted Source. Glioblastoma is a challenging cancer to treat and has an average five-year survival rate of 6.9%. Now, researchers from
SAN FRANCISCO - UC San Francisco researchers have designed a candidate drug that could help make pancreatic cancer, which is almost always fatal, a treatable, perhaps even curable, condition. Pancreatic cancer is less common than these other cancers, but the lack of treatment options makes it more deadly, and it claims more than 50,000 lives
